drugset / Trial / NCT01381666

Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)

NCT01381666 ↗

Phase 2 Terminated 22 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverQuadruple-blind

Summary

The objective of the present work is to explore and compare the diagnostic quality of sputum specimens obtained by BAL, induction with hypertonic saline (3%), and induction with INS316 in patients diagnosed with interstitial lung diseases.

Timeline

Start
2003-01
Primary completion
2004-04
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject INS316 Diagnostic / imaging agent — Inhaled